With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
A solution of 1, 1-dimethylethyl (2S)-2-methyl-1-piperazinecarboxylate (Intermediate 26,100 mg, 0.5 mmol) in CH2CI2 (5 mL) was mixed with 3-bromo benzaldehyde (0.06 mL, 0.5 mmol) and NaB (OAc) 3H (0.16 g, 0.75 mmol). The resulting mixture was stirred for 12 hours, diluted with dichloromethane (30 mL) and washed with brine (50 mL). The organic layer was collected, dried over Na2SO4 and concentrated. Separation via a combiflash system then afforded the title compound (150 mg, 81%). LC/MS : m/z, 369 (M+H) ;’HNMR (MeOD) 1.26 (3H, d), 1.47 (9H, s), 2.0 (1H, m), 2.1 (1H, m), 2.6 (1H, m), 2.8 (1H, m), 3.1 (1H, m), 3.3 (2H, s), 3.4 (1 H, m), 3.5 (1 H, m), 3.8 (1 H, m), 4.2 (1 H, m), 4.88 (1 H, s), 7.25 (1 H, m), 7.3 (1 H, m), 7.4 (1 H, m), 7.55 (1 H, s)., 169447-70-5
As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.
Reference£º
Patent; GLAXO GROUP LIMITED; WO2005/87236; (2005); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics